R-327 is under clinical development by Recce Pharmaceuticals and currently in Phase I for Influenza A Virus, H1N1 Subtype Infections. According to GlobalData, Phase I drugs for Influenza A Virus, H1N1 Subtype Infections have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how R-327’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

R-327 overview

R-327 is under development for the treatment of bacterial sepsis caused by methicillin resistant Staphylococcus aureus (MRSA), carbapenem-resistant gram-negative (CRE) Escherichia coli, an intestinal infection caused by E coli, influenza A (H1N1) infections and S. aureus (Gram-positive and Gram-negative bacterial burn wound infections), coronavirus disease 2019 symptoms caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), burns, Neisseria gonorrhoeae infections, enterococcus faecium, klebsiella pneumoniae, acinetobacter baumannii, mycobacterium infections and pseudomonas aeruginosa, Clostridium perfringens infections and Streptococcus pyrogenes infections. It is also under development for the treatment of urinary tract infection and diabetic foot ulcer. The therapeutic candidate constitutes polymeric antibiotic. The drug candidate is administered through intravenous, intranasal, inhalational, topical and oral routes. The drug candidate targets outer wall protein. It was also under development for the treatment of cancers such as colon cancer, gastritis, helicobacter pylori Infections, skin and skin structure infections (SSSI) caused by bacteria.

Recce Pharmaceuticals overview

Recce Pharmaceuticals, formerly Recce Ltd is a pre-clinical stage pharmaceutical company that offers the development and commercialization of a new class of antibiotics for human use. It develops and discovers products such as a new class of synthetic antibiotics, commercial antibiotics, RECCE 327, synthetic polymer antibiotics, significant antibiotic medicines and RECCE antibodies. It offers services such as planned Phase I and Phase II clinical trials, patent and patent application ownership, covering composition of matter, manufacturing and therapeutic applications. Recce also provides manufacturing, discovery, producing, clinical trial and research, pre-clinical testing, clinical pathway services and other services. Recce Pharmaceuticals is headquartered in Sydney, New South Wales, Australia.

For a complete picture of R-327’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.